What top creators are saying about Moderna, Inc.(MRNA)

Appeared in a performance screen as having risen about 700%; this was historical performance context, not a fundamental assessment or recommendation.

The speaker offered no clear directional view, mentioning high demand and heavy ownership while noting that the drug under discussion was not FDA-approved.

Mentioned as an example of a company with specialized biotech knowledge that could benefit from adding expertise to AI models; the discussion did not establish a specific investment case.

Asked whether Moderna was a short, the speaker said he did not know and offered no supporting analysis.

The discussion is strongly critical of Moderna’s COVID-19 vaccine and vaccine policy, alleging safety problems, but offers no valuation or specific investment recommendation.

Cited as a year-to-date leader with an approximate 700% gain; this was a historical performance observation, not an endorsement or forecast.

The speaker was unsure whether Moderna was a short; no clear bullish or bearish view was given.

Cited as a strong year-to-date performer in a screening example; past performance was explicitly not presented as a forecast or recommendation.

Moderna was used hypothetically to illustrate how a major medical breakthrough can trigger a sharp market repricing. No current investment thesis or recommendation was presented.

Moderna was mentioned only as a comparison in a comment about a cancer player; no standalone view of its business or prospects was given.

Mentioned only as a comparison when the speaker suggested Genmab was the more compelling cancer-related opportunity; no independent analysis was provided.

A speaker was surprised the stock had performed well despite political concerns, but offered no valuation view or recommendation.

The speaker characterized clinical-trial data as not very good and noted patient deaths, while discussing volatile price action and advising against shorting immediately; no long-term conclusion or price target was given.

The discussion was bearish on Moderna's valuation under more modest cancer-vaccine sales assumptions. Weak cited mRESVIA revenue and reliance on its COVID vaccine add to the challenge, although successful expansion of its cancer-vaccine program could create substantial upside.

Cited as an example of a company-specific news event reportedly prompting a 400% jump in activity in its Injective market. This is an anecdote, not a forecast or investment recommendation.

The speakers were cautiously positive about Moderna's cancer-vaccine opportunity with Merck, while noting competition from Keytruda and uncertainty over which company would capture the value.

Trial news involving patient deaths raised concerns, but the stock recovered; the speaker said he would stop shorting it because the price action no longer supported the short thesis.

Moderna was reported up about 2% in brief real-time market commentary, with no longer-term view or recommendation.

Listed among stocks with heavy trading volume; the chart shows mixed daily buy/sell ratios.

Cited as an example of a biotech stock that had risen 553% through September despite a major decline, illustrating the sector's substantial volatility.

The speaker said Moderna had further downside and recommended shorting it, noting that recent data was widely expected and two drugs had failed in succession. He also acknowledged that the company has had successful outcomes and that drug development is uncertain.

Its personalized cancer treatment succeeded in a Phase 3 trial, but the 42% reduction in recurrence or death was below investor expectations, contributing to a sharp stock decline. The treatment is used with Keytruda and may take about six months to show effectiveness.

Its personalized cancer treatment succeeded in a large Phase 3 trial, but the 42% reduction in relative risk was below investor expectations. Shares fell sharply after the results; the discussion was mixed and offered no investment recommendation.

The speaker said the announcement contained little new information, explicitly called for shorting Moderna, and expected further downside, while acknowledging unpredictable biotech outcomes.

Shares fell sharply and were halted after a leaked memo reportedly suggested a personalized cancer vaccine worked less well when used with another drug, highlighting clinical-news and sudden-move risks.

Shares fell about 15% after reports of leaked, unverified cancer-vaccine trial data; the discussion concerned a high-risk event-driven short trade, not a general recommendation.

Moderna was mentioned as falling during the session, without company-specific investment analysis.

Mentioned as an example of a relatively defensive stock attracting investor interest during the sell-off.

Cited as an example of AI helping teams turn complex data into experimental workflows for research and development. No valuation, stock-performance view, or investment recommendation was provided.

The speaker presented a valuation-driven short thesis, citing weak mRESVIA sales and the large revenue assumptions needed to justify the current share price. The cancer-vaccine candidate offers potential upside, but its development, approval, and commercial prospects remain uncertain.

Mentioned in market commentary without detailed new investment analysis.

Anson was short ahead of a cancer-treatment trial readout, viewing expectations as excessive after a roughly 100% rise; Kassam acknowledged that positive trial results could undermine the short thesis.

Shkreli said he thought Moderna was a short, but supplied no explanation, catalyst, target, or time horizon.

The speaker viewed Moderna as overvalued around $234–$235 per share. The valuation depends on unapproved cancer-vaccine products achieving exceptional sales, while current COVID-related products and mRESVIA were described as weak.

The host was skeptical of the valuation, saying the cancer-vaccine opportunity would require exceptionally large revenue to justify the share price. Intismeran autogene data expected at ESMO on October 24 was a key catalyst, but commercial prospects and pipeline outcomes were uncertain.

The image showed the stock declining amid broad selling pressure.

The stock was rallying strongly, but the speaker said it was difficult to know whether the rally would continue. Possible Phase 3 disclosure was mentioned without a known outcome or clear bull thesis.

The speaker said the stock had experienced a substantial run, illustrating biotech capital flows rather than offering a company-specific analysis or recommendation.

Moderna had sharp price swings, but the host offered no confirmed fundamental explanation. He cautioned against treating speculative options activity or an unverified AI drug-discovery narrative as investment evidence.

Mentioned as an example in a skeptical discussion of AI-enabled drug development, not as an investment recommendation.

Mentioned as a biotech stock that had recently risen, in contrast to Abivax and Spruce; no recommendation or company-specific thesis was provided.

Described as rallying strongly, but the speaker was uncertain whether the rally would continue and uncertain about an upcoming Phase 3 disclosure.

The discussion noted a potentially meaningful cancer drug alongside litigation, drug-label efforts, liquidity concerns, and potentially irrational retail-driven share movement.

The speaker described Moderna as a short and said he did not understand why the stock was rising; no target or timeline was given.

Cited as a biotech stock that had risen while some other biotech shares fell; no company-specific outlook or recommendation was given.

The stock was among those that fell; the discussion provided no specific company analysis.

The speaker questioned whether Moderna's rally was retail-driven or irrational, while acknowledging its cancer-drug program as a meaningful development.

Moderna had recently risen sharply and was described as a strong S&P 500 performer, but no specific investment thesis was provided.

The speaker said they were short, citing competition and uncertainty about whether Moderna could repeat its COVID-era success.

The speaker called the rising stock a good short opportunity around $213–$215, describing the move as occurring for no apparent reason; no price target or holding period was given.